Houston, TX, United States of America

Alemayehu Gorfe Abebe

USPTO Granted Patents = 2 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2021-2025

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Alemayehu Gorfe Abebe

Introduction

Alemayehu Gorfe Abebe is a notable inventor based in Houston, TX (US). He has made significant contributions to the field of therapeutic interventions, particularly in cancer treatment. With a total of 2 patents, his work focuses on innovative methods and compositions that target critical pathways in cancer biology.

Latest Patents

One of Alemayehu's latest patents is centered around "Methods and compositions for KRAS inhibitors." This patent discloses compounds that act as allosteric inhibitors of KRAS, which are crucial for therapeutic intervention in various disorders, including cancer. The compounds described are substituted 7-(piperazin-1-yl)pyrazolo[1,5-a]pyrimidine analogs. These compounds can be utilized in methods of treating cancer, showcasing their potential in clinical applications.

Career Highlights

Alemayehu Gorfe Abebe is affiliated with the University of Texas System, where he continues to advance his research and innovation in the field of cancer therapeutics. His work is characterized by a commitment to developing effective treatments that can significantly impact patient outcomes.

Collaborations

Alemayehu collaborates with esteemed colleagues, including Michael J McCarthy and Cynthia V Pagba. These partnerships enhance the research efforts and contribute to the development of groundbreaking therapeutic strategies.

Conclusion

Alemayehu Gorfe Abebe's contributions to the field of cancer treatment through his innovative patents highlight his role as a leading inventor. His work not only advances scientific knowledge but also holds promise for improving therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…